4W2R: Structure Of Hsacprc2 In Complex With 5,8-Dichloro-2-[(4-Me Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy Yl)Methyl]-3,4-Dihydroisoquinolin-1(2h)-One
reference: Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: Identification of development candidate (R)-5,8-dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)., Kung PP, Bingham P, Brooun A, Collins MR, Deng YL, Dinh DM, Fan C, Gajiwala KS, Grantner R, Gukasyan HJ, Hu W, Huang B, Kania RS, Kephart SE, Krivacic CT, Kumpf RA, Khamphavong P, Kraus M, Liu W, Maegley KA, Nguyen L, Ren S, Richter DT, Rollins RA, Sach NW, Sharma S, Sherrill J, Spangler JE, Stewart AE, Sutton SC, Uryu S, Verhelle D, Wang H, Wang S, Wythes M, Xin S, Yamazaki S, Zhu H, Zhu J, Zehnder L, Edwards MP, J Med Chem. 2017 Dec 6. doi: 10.1021/acs.jmedchem.7b01375. PMID: 29211475

This OCA Structure page
uses Jmol, developed by the Jmol Development Team (documentation).